Arvinas (ARVN) Q1 2026 earnings review
First PROTAC Approval Validates Platform, Focus Shifts to Pipeline
Arvinas achieved a historic milestone with the FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC therapy. Crucially, management executed exactly what they promised in prior quarters: securing approval and immediately out-licensing global commercialization rights to Rigel Pharmaceuticals. This eliminates the massive commercial launch cost overhang that had previously concerned investors. The Q1 financials reflect a significantly leaner, refocused company following its 2025 restructuring. Total operating expenses fell 32% YoY to $79.4 million. With $615 million in total liquidity and a quarterly cash burn of $67.5 million, the company's cash runway into the second half of 2028 remains highly secure. The investment thesis has now cleanly pivoted from late-stage commercialization risk to early-stage clinical pipeline execution.
🐂 Bull Case
The FDA approval of VEPPANU is the first for any PROTAC degrader, providing massive external validation for Arvinas's core scientific platform and mechanism of action.
By licensing VEPPANU to Rigel Pharmaceuticals, Arvinas avoids building an expensive commercial infrastructure, protecting its balance sheet while retaining upside.
🐻 Bear Case
With the VEPPANU commercial rights licensed out, Arvinas returns to being a pure-play clinical-stage biotech. Revenue reversed sharply from $188.8M in 25Q1 to $15.6M in 26Q1, and future top-line numbers will rely entirely on sporadic milestones.
The company's future value is now entirely dependent on early-stage Phase 1 readouts in highly competitive spaces, such as KRAS G12D (ARV-806) and BCL6 (ARV-393).
⚖️ Verdict: 🟢
Bullish. Management delivered on their primary strategic objective: getting VEPPANU approved and partnered before the PDUFA date. The balance sheet is clean, the burn rate is under control, and the scientific platform is now FDA-validated.
Key Themes
VEPPANU Approval and Rigel Licensing Deal
The FDA approved VEPPANU for ESR1-mutated advanced breast cancer, and NCCN immediately added it to their clinical guidelines as a Category 2A treatment. More importantly for the balance sheet, Arvinas and Pfizer entered a license agreement with Rigel Pharmaceuticals for exclusive global rights. This perfectly executes management's stated goal from late 2025 to find a third-party commercial partner, eliminating the risk of a botched, under-funded solo launch.
Operating Expense Contraction Accelerating
The financial benefits of the 2025 corporate restructuring (which cut one-third of the workforce) are now fully visible. GAAP R&D expenses decelerated sharply, dropping $30.5M YoY to $60.3M, driven primarily by a $15.2M reduction in vepdegestrant program costs. General and administrative expenses also fell $7.5M YoY to $19.1M. This disciplined cost control is successfully stretching the cash runway.
ARV-102 Biomarker Validation in Parkinson's
Data presented at the AD/PD 2026 conference showed ARV-102 achieved greater than 50% LRRK2 degradation in the cerebrospinal fluid (CSF) of Parkinson's patients treated for 28 days. Crucially, it also showed a reduction in key neuroinflammatory biomarkers (CD68, GPNMB). This proves the PROTAC can cross the blood-brain barrier and hit its target in humans, a massive de-risking event for the neurology pipeline.
ARV-102 Trial Timeline Slippage
While the ARV-102 Phase 1 data is encouraging, the timeline for the next step is decelerating. In Q4 2025, management guided to initiating the Phase 1b trial in Progressive Supranuclear Palsy (PSP) in '1H 2026'. In the current Q1 2026 release, this guidance has slipped to '2H 2026, pending regulatory feedback', suggesting minor friction or extended dialogues with the FDA.
Revenue Reversal and the Milestone Cliff
Revenue reversed sharply, plunging from $188.8M in 25Q1 to just $15.6M in 26Q1. The prior year's figure was inflated by a non-cash accounting adjustment related to Pfizer, but the stark drop highlights the new reality: Arvinas will generate minimal recurring revenue until Rigel successfully launches VEPPANU and triggers royalty or milestone payments.
Other KPIs
Decelerating gracefully. Comprised of $87.3M in cash and $527.6M in marketable securities. The company consumed $67.5M in cash for operations during the quarter. This robust balance sheet clarifies the bizarre analyst confusion from the Q4 2025 earnings call (where an analyst mistakenly cited an '$85M cash balance' by ignoring marketable securities). The balance sheet remains a core strength.
Reversing. The company reported a net loss of $57.6M, a sharp reversal from the $82.9M net income reported in 25Q1. However, the 25Q1 profit was entirely driven by a massive, one-time $188.8M revenue recognition adjustment from the Pfizer collaboration. The current -$57.6M loss is actually a sequential improvement from the -$67.4M loss in 25Q4, reflecting ongoing cost controls.
Guidance
Stable. The company reiterated its guidance that current liquidity is sufficient to fund operations well into late 2028. This implies a steady state cash burn of roughly $60M-$70M per quarter, which aligns perfectly with Q1 2026 actuals.
Decelerating. This metric slipped from prior guidance of 1H 2026. The company explicitly cited 'pending regulatory feedback' as the gating factor. A potential registrational trial in PSP is still modeled for late 2026.
Stable. Management remains on track to bring its first immuno-oncology clinical candidate into trials for patients with advanced solid tumors.
Key Questions
Rigel Deal Economics
The press release announces the VEPPANU out-licensing to Rigel but omits the financial terms. What are the specific economics (upfront payments, milestones, royalty tiers) of this deal, and how are these economics split between Arvinas and Pfizer?
ARV-102 Regulatory Friction
The initiation of the ARV-102 Phase 1b trial in PSP shifted from 1H to 2H 2026. What specific regulatory feedback is the FDA requesting that caused this delay?
ARV-393 Efficacy Thresholds
With the BCL6 degrader ARV-393 seeing multiple responses in early cohorts at doses 'below the predicted effective exposure level', what is the updated timeline for identifying the recommended Phase 2 dose?